Methamphetamine (MA) use is associated with activation of microglia and, at high doses, can induce neurotoxicity. Given the changes in the neuroinflammatory environment associated with MA, we investigated whether MA sensitization, a model of stimulant psychosis and an indicator of drug addiction, would interfere with the thermoregulatory and neuroinflammatory response to a subsequent peripheral immune stimulus. C57BL6/J mice were given either 1 mg/kg MA or saline i.p. once a day for 5 days to produce behavioral sensitization. Seventy-two hours following the last MA injection, 100 lg/kg LPS or saline was co-administered with 1 mg/kg MA or saline and blood and brains were collected. Here we report that while co-administration of LPS and MA did not affect the LPS-induced increase in central cytokine mRNA, mice sensitized to MA showed an attenuated central response to LPS. Interestingly, the peripheral response to LPS was not affected by MA sensitization. Plasma cytokines increased similarly in all groups after LPS. Further, c-Fos expression in the nucleus of the solitary tract did not differ between groups, suggesting that the periphery-to-brain immune signal is intact in MA-sensitized mice and that the deficit lies in the central cytokine compartment. We also show that MA sensitization decreased LPS-or acute MAinduced microglial Iba1 expression compared to non-sensitized mice. Taken together, these data show that MA sensitization interferes with the normal central immune response, preventing the CNS from efficiently responding to signals from the peripheral immune system.
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Introduction
Methamphetamine (MA) is one of the most commonly abused drugs in the US Approximately 10.4 million Americans 12 years of age or older have used MA for non-medical reasons at least once in their lifetimes (NSDUH, 2005) . MA is a functional dopamine agonist (Chang et al., 2004) and its effects may last for hours, adding to its potent addictive qualities. Repeated administration of MA in animals produces a phenotype that is characterized by behavioral sensitization to the locomotor enhancing effects of the drug and has been extensively used as a model of stimulant psychosis (Ujike, 2002) and as an indicator of drug addiction (Robinson and Berridge, 1993) . This behavioral sensitization is long-lasting and can be reinstated after chronic administration has ceased. It represents a convergence of complex, long-term molecular changes and alterations in gene expression in the addicted brain (Nestler and Malenka, 2004) .
There are several reports demonstrating that chronic pre-treatment with low-dose MA, a schedule that can produce sensitization, attenuates the neurotoxic effects of a subsequent, high-dose MA challenge (Cadet et al., 2009; Danaceau et al., 2007; Graham et al., 2008; Johnson-Davis et al., 2003; Stephans and Yamamoto, 1996) , however little is known concerning the neuroinflammatory consequences of MA use and subsequent peripheral immune stimulation. In addition to its effects on the monoaminergic system, MA use is associated with cognitive deficits (Dellu et al., 2000) and long-term MA users show prominent microglial activation in certain brain regions that are sometimes apparent almost 2 years after MA use had ceased (Sekine et al., 2008) . MA-induced microglial activation has also been shown in animals given neurotoxic doses of MA (Fantegrossi et al., 2008; Hozumi et al., 2008; Thomas and Kuhn, 2005) and there is evidence that both high and low doses of MA can induce inflammatory cytokines such as tumor necrosis factor a (TNFa) and interleukin-1b (IL-1b) in the brains of rodents (Flora et al., 2003; Halladay et al., 2003; Nakajima et al., 2004; Numachi et al., 2007) . Acute and chronic MA administrations have been shown to reduce the numbers of leukocytes as well as the NK cell activity of splenic lymphocytes (Saito et al., 2008) . Chronic MA administration reduced Con A-induced T-cell proliferation as well as IL-2 and IFNc production in mouse splenocytes (Yu et al., 2002) . MA has also been shown to decrease IL-1 production by splenocytes in mice (In et al., 2005) and reduced IFNc and IL-10 while increasing IL-4, MCP-1 and TNFa in plasma (Hozumi et al., 
